Cargando…
Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations
More than 75% of epithelial ovarian cancer (EOC) patients experience disease recurrence after initial treatment, highlighting our incomplete understanding of how chemoresistant populations evolve over the course of EOC progression post chemotherapy treatment. Here, we show how two paclitaxel (PTX) t...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628134/ https://www.ncbi.nlm.nih.gov/pubmed/37932310 http://dx.doi.org/10.1038/s41598-023-46055-6 |